Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses
暂无分享,去创建一个
E. Simonsen | C. Gluud | O. J. Storebø | H. B. Krogh | M. Holmskov | F. L. Magnusson | E. Faltinsen | Adnan Todorovac | Trine Gerner | Erica Ydedahl-Jensen
[1] R. Dalrymple,et al. NICE guideline review: Attention deficit hyperactivity disorder: diagnosis and management (NG87) , 2019, Archives of Disease in Childhood.
[2] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.
[3] J. Davies. How Voting and Consensus Created the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) , 2017, Anthropology & medicine.
[4] I. Hambleton,et al. The Use and Reporting of the Cross-Over Study Design in Clinical Trials and Systematic Reviews: A Systematic Assessment , 2016, PloS one.
[5] E. Simonsen,et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). , 2023, The Cochrane database of systematic reviews.
[6] K. Dickersin,et al. Design, Analysis, and Reporting of Crossover Trials for Inclusion in a Meta-Analysis , 2015, PloS one.
[7] P. Sedgwick. Bias in randomised controlled trials: comparison of crossover group and parallel group designs , 2015, BMJ : British Medical Journal.
[8] T. Banaschewski,et al. An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder , 2014, Expert opinion on drug metabolism & toxicology.
[9] Ethan M Balk,et al. Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials , 2012, Annals of Internal Medicine.
[10] A. Karni,et al. Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial , 2012, ADHD Attention Deficit and Hyperactivity Disorders.
[11] E. Simonsen,et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents , 2012 .
[12] Maria Blettner,et al. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. , 2012, Deutsches Arzteblatt international.
[13] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[14] G. Guyatt,et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.
[15] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[16] B. Bourgeois,et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy , 2010, Epilepsy & Behavior.
[17] D. Segal. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .
[18] L. Rohde,et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. , 2009, Journal of child and adolescent psychopharmacology.
[19] Gordon H Guyatt,et al. Design, analysis, and presentation of crossover trials , 2009, Trials.
[20] Douglas G. Altman,et al. Chapter 16: Special Topics in Statistics , 2008 .
[21] Joseph S. Raiker,et al. Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. , 2008, Journal of child and adolescent psychopharmacology.
[22] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.
[23] L. Rohde,et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. , 2008, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[24] J. Ioannidis,et al. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. , 2007, International journal of epidemiology.
[25] B. Pennington,et al. Modeling Rater Disagreement for ADHD: Are Parents or Teachers Biased? , 2007, Journal of abnormal child psychology.
[26] P. Moore,et al. Assessing the trade‐offs between crossover and parallel group designs in sleep research , 2006, Journal of sleep research.
[27] Douglas G Altman,et al. Meta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry‐over , 2002, Statistics in medicine.
[28] Douglas G Altman,et al. Meta-analyses involving cross-over trials: methodological issues. , 2002, International journal of epidemiology.
[29] Christian Gluud,et al. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.
[30] A. Richens. Proof of efficacy trials: cross-over versus parallel-group , 2001, Epilepsy Research.
[31] M P Becker,et al. Marginal modeling of binary cross-over data. , 1993, Biometrics.
[32] Stephen Senn,et al. Cross-over trials in clinical research , 1993 .
[33] B. Everitt,et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour , 1987, Psychological Medicine.
[34] M. Gillian,et al. How to define Treatment Emergent Adverse Event ( TEAE ) in crossover clinical trials ? , 2017 .
[35] M. Wolraich,et al. Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate , 2004, CNS drugs.
[36] T. Banaschewski,et al. Comparative efficacy of once–a–day extended–release methylphenidate, two–times–daily immediate–release methylphenidate, and placebo in a laboratory school setting , 2004, European Child & Adolescent Psychiatry.
[37] D. Abernethy,et al. Pharmacokinetics and Clinical Effectiveness of Methylphenidate , 1999, Clinical pharmacokinetics.